COMP <GO>
CYTK vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
Cytokinetics Incorporated (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CYTK 2
— MRK 12
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: MRK
LAST: $62.99 (-0.51%) • MKT CAP: $8.80B
balance-sheet
0.45
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYTK VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYTK | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.08% | 3.42% | -9.50 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | CYTK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.45 | 5.19 | -4.74 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | CYTK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.0 | 56.9 | -10.87 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.92 | -0.05 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 18.4x | +12.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.80B | $361.02B | -$352.22B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYTK REV | MRK REV | CYTK GROSS % | MRK GROSS % | CYTK FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $88.0M | $65.01B | 44.0% | 74.8% | -$534.8M | $12.36B |
| FY 2024 | $18.5M | $64.17B | 44.0% | 76.3% | -$399.8M | $18.10B |
| FY 2023 | $7.5M | $60.12B | 44.0% | 44.0% | -$414.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYTK // BETA 0.87
MRK // BETA 0.92